Clinical Trial News and Research

RSS

Identifying key brain circuit opens doors for new psychosis treatments

Our study investigated the brain circuits involved in psychosis-a condition characterized by delusions, hallucinations, disorganized thinking and detachment from reality.

13 Feb 2025

Low-dose semaglutide reduces alcohol consumption and cravings in early trial

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for treating alcohol use disorder.

13 Feb 2025

Selkirk Pharma introduces ClinFAST™ to expedite fill/finish for clinical trials

Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the launch of ClinFAST™, a paradigm-shifting service designed to assist clinical stage biotech and pharma companies with a rapid fill/finish process for clinical trial supplies.

13 Feb 2025

UCLA team identifies brain rhythms linked to seizures in Alzheimer's

A UCLA Health research team has identified changes in brain rhythms that indicate seizure activity in Alzheimer's patients.

13 Feb 2025

Olpasiran significantly lowers "bad cholesterol" linked to cardiovascular risk

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai researcher of a phase 2 trial.

13 Feb 2025

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

From MaxCyte, Inc. 13 Feb 2025

Blockbuster drug for diabetes and obesity could also help reduce alcohol intake

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new USC research.

12 Feb 2025

University of Michigan tests novel mechanical heart pump in clinical trial

A cardiac surgery and heart failure team at the University of Michigan implanted a novel mechanical heart pump into a patient as part of a clinical trial that will compare it to the only device currently used to treat end-stage heart failure.

12 Feb 2025

New immune map uncovers key pancreatic cancer insights

Researchers determine a complex immune infiltrate pattern based on a newly constructed immune map developed using pancreatic cancer cells.

12 Feb 2025

Scientists discover brain mechanism behind nicotine withdrawal

According to the World Health Organization (WHO), over 22% of the global population smokes, with more than 9 million smoking-related deaths reported annually.

12 Feb 2025

Gut microbiota key to predicting sensitivity to common food additives

Widely used by the food industry, emulsifiers – a type of food additive – are found in many daily foods (sliced bread, ice creams, crème fraîche, plant milks, etc.).

11 Feb 2025

Short-course, higher dose vaginal brachytherapy for endometrial cancer shown to be effective

In a randomized clinical trial, researchers from Huntsman Cancer Institute at the University of Utah (the U) have found that short-course, higher dose vaginal brachytherapy for endometrial cancer had similar effectiveness to more frequent, lower dose sessions.

11 Feb 2025

UVA launches trial to test AI-powered device for diabetes management

For people living with Type 1 Diabetes (T1D), keeping blood sugar levels in check is a constant challenge.

11 Feb 2025

Study explores microbiome reboot to prolong effect of Crohn's disease therapy

A special liquid diet, known as exclusive enteral nutrition, is an essential therapy for Crohn's disease. Patients consume only this formula for six to eight weeks, completely avoiding solid foods. However, the exact reasons why this is helpful were previously unclear.

11 Feb 2025

NIH clinical trial examines investigational therapy for dengue

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.

11 Feb 2025

Daily fruit and vegetable extracts may boost brain power

A study reveals polyphenol-rich nutraceuticals enhance cognitive performance and boost neuroprotective biomarkers, offering a dietary approach to brain health.

11 Feb 2025

Vancomycin could offer new therapeutic option for patients with a type of inflammatory bowel disease

An antibiotic used to treat infective diarrhoea could be an effective drug for a type of inflammatory bowel disease, a new study has found.

10 Feb 2025

Children with peanut allergy achieve tolerance with gradual peanut butter ingestion

Eating gradually increasing doses of store-bought, home-measured peanut butter for about 18 months enabled 100% of children with peanut allergy who initially could tolerate the equivalent of at least half a peanut to consume three tablespoons of peanut butter without an allergic reaction, researchers report.

10 Feb 2025

New minimally invasive treatment offers hope for primary aldosteronism

Doctors at Queen Mary University of London, Barts Health NHS Trust, and University College London have led the development of a simple, minimally invasive Targeted Thermal Therapy (Triple T) that has the potential to transform medical management of a common, but commonly overlooked, cause of high blood pressure.

10 Feb 2025

Ariceum Therapeutics receives FDA’s Orphan Drug Designation for targeted radionuclide cancer treatment

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer (SCLC).

10 Feb 2025